Skip to content
Parakho

Granules India Ltd-$

NSE GRANULESBSE 532482granulesindia.comInvestor relations

Q1 FY27, unaudited

Revenue
₹801.88 Cr
Profit after tax
₹71.75 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations801.88−1.03%3,473.96
Other income13.78+4.81%49.80
Total income815.66−0.94%3,523.76
Employee benefit expense113.18+6.89%423.13
Finance costs9.61−29.69%61.44
Depreciation & amortisation39.06−1.13%164.47
Total expenses719.10−0.09%2,975.79
Profit before tax96.56+5.60%535.81
Tax expense24.82+13.00%135.15
Profit after tax71.75+3.25%400.67
Total comprehensive income95.65+39.32%365.03
Earnings per share
Earnings per share, basic₹2.90₹16.48
Earnings per share, diluted₹2.84₹16.47

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q2 FY27

Management presented Granules India's strategic transformation, outlining four growth engines: controlled substances, complex generics and early market opportunities, oncology, and peptide CDMO. The company reported that complex generics grew from 1% of revenue in FY20 to 33% in FY26, gross margin expanded by about 15 percentage points to 65% over four years, and EBITDA margin rose three percentage points to 22%. Management also discussed a planned organic capital expenditure of about 2,000 crore over the next three to four years to support these growth engines.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q1 FY27 · Q4 FY26 · All quarters

Filings

12 shown · 50 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.